Quest Pharmatech’s Collapse: Why Investors Must Scrutinize Its Faulty Immunotherapy Claims
Quest Pharmatech’s steep decline and lack of revenue warn investors: its flat stock, low volume and below‑SMA price signal a risky biotech bubble.
4 minutes to read